DE69231062D1 - Morphogen-induzierte Modulation von entzündlichen Antworten - Google Patents

Morphogen-induzierte Modulation von entzündlichen Antworten

Info

Publication number
DE69231062D1
DE69231062D1 DE69231062T DE69231062T DE69231062D1 DE 69231062 D1 DE69231062 D1 DE 69231062D1 DE 69231062 T DE69231062 T DE 69231062T DE 69231062 T DE69231062 T DE 69231062T DE 69231062 D1 DE69231062 D1 DE 69231062D1
Authority
DE
Germany
Prior art keywords
morphogen
inflammatory responses
induced modulation
methods
tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69231062T
Other languages
English (en)
Other versions
DE69231062T2 (de
DE69231062T3 (de
Inventor
Thangavel Kuberasampath
Roy H L Pang
Hermann Oppermann
David C Rueger
Charles N Cohen
Engin Ozkaynak
John E Smart
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stryker Corp
Original Assignee
Creative Biomolecules Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27419430&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69231062(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Creative Biomolecules Inc filed Critical Creative Biomolecules Inc
Publication of DE69231062D1 publication Critical patent/DE69231062D1/de
Publication of DE69231062T2 publication Critical patent/DE69231062T2/de
Application granted granted Critical
Publication of DE69231062T3 publication Critical patent/DE69231062T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02—Preservation of living parts
    • A01N1/0205—Chemical aspects
    • A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
    • A01N1/0226—Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/24—Collagen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C07K14/625—Extraction from natural sources
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2310/00—Prostheses classified in A61F2/28 or A61F2/30 - A61F2/44 being constructed from or coated with a particular material
    • A61F2310/00005—The prosthesis being constructed from a particular material
    • A61F2310/00365—Proteins; Polypeptides; Degradation products thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
DE69231062T 1991-08-30 1992-08-28 Morphogen-induzierte Modulation von entzündlichen Antworten Expired - Lifetime DE69231062T3 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US752764 1985-07-08
US75305991A 1991-08-30 1991-08-30
US75286191A 1991-08-30 1991-08-30
US75276491A 1991-08-30 1991-08-30
US753059 1991-08-30
US752861 1991-08-30
PCT/US1992/007358 WO1993004692A1 (en) 1991-08-30 1992-08-28 Morphogen-induced modulation of inflammatory response

Publications (3)

Publication Number Publication Date
DE69231062D1 true DE69231062D1 (de) 2000-06-21
DE69231062T2 DE69231062T2 (de) 2001-02-15
DE69231062T3 DE69231062T3 (de) 2004-07-29

Family

ID=27419430

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69231062T Expired - Lifetime DE69231062T3 (de) 1991-08-30 1992-08-28 Morphogen-induzierte Modulation von entzündlichen Antworten

Country Status (8)

Country Link
EP (1) EP0601106B2 (de)
JP (1) JP3693338B2 (de)
AT (1) ATE192931T1 (de)
AU (1) AU669127B2 (de)
CA (1) CA2116562C (de)
DE (1) DE69231062T3 (de)
ES (1) ES2149776T5 (de)
WO (1) WO1993004692A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688678A (en) * 1990-05-16 1997-11-18 Genetics Institute, Inc. DNA encoding and methods for producing BMP-8 proteins
US7378392B1 (en) 1990-05-16 2008-05-27 Genetics Institute, Llc Bone and cartilage inductive proteins
CA2104678C (en) 1991-03-11 2002-05-14 Charles M. Cohen Protein-induced morphogenesis
US5972884A (en) * 1991-03-11 1999-10-26 Creative Biomolecules, Inc. Morphogen treatment of gastrointestinal ulcers
US6399569B1 (en) 1991-03-11 2002-06-04 Curis, Inc. Morphogen treatments for limiting proliferation of epithelial cells
KR100255415B1 (ko) * 1991-06-25 2000-05-01 브루스 엠. 에이센 비엠피-9 조성물
US6287816B1 (en) 1991-06-25 2001-09-11 Genetics Institute, Inc. BMP-9 compositions
WO1994006447A2 (en) * 1992-09-15 1994-03-31 Creative Biomolecules, Inc. 60a protein-induced morphogenesis
AU719153B2 (en) * 1992-09-15 2000-05-04 Creative Biomolecules, Inc. Morphogen treatment of gastrointestinal ulcers
WO1994006420A2 (en) * 1992-09-15 1994-03-31 Creative Biomolecules, Inc. Morphogen treatment of gastrointestinal ulcers
CA2144514C (en) * 1992-09-16 2002-03-26 Thangavel Kuberasampath Morphogen-induced liver regeneration
AU734312B2 (en) * 1996-03-22 2001-06-07 General Hospital Corporation, The Administration of polypeptide growth factors following central nervous system ischemia or trauma
US6498142B1 (en) 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
US6034062A (en) * 1997-03-13 2000-03-07 Genetics Institute, Inc. Bone morphogenetic protein (BMP)-9 compositions and their uses
EP0980252B1 (de) 1997-05-05 2004-10-06 Curis, Inc. Therapien zur behandlung von akutem nierenversagen
WO1998054572A1 (en) 1997-05-30 1998-12-03 Creative Biomolecules, Inc. Methods for evaluating tissue morphogenesis and activity
US7147839B2 (en) 1998-05-29 2006-12-12 Curis, Inc. Methods for evaluating tissue morphogenesis and activity
EP1298434A1 (de) * 2001-10-01 2003-04-02 Cognis France S.A. Verfahren zum Auffinden neuer Wirkstoffe mit androgen-ähnlichen Eigenschaften
AU2002308204B9 (en) 2001-11-19 2008-06-12 Scil Technology Gmbh Device having osteoinductive and osteoconductive properties
EP1572950B1 (de) 2002-06-17 2012-10-10 Thrasos, Inc. Einzeldomäne-tdf-verwandte verbindungen und analoge davon
DK1539261T3 (da) 2002-09-10 2006-08-07 Scil Technology Gmbh Metalimplantat belagt under nedsat oxygenkoncentration med osteoinduktiv protein
DE602005022998D1 (de) 2004-03-10 2010-09-30 Scil Technology Gmbh Überzogene implantate, ihre herstellung und verwendung davon
EP2789342A1 (de) 2004-06-17 2014-10-15 Thrasos Innovation, Inc. Verbindungen im Zusammenhang mit TDF und Analoga davon
CA2863125A1 (en) 2005-09-20 2007-03-29 Thrasos Innovation, Inc. Tdf-related compounds and analogs thereof
US20080020014A1 (en) * 2006-07-19 2008-01-24 Paul Consigny Implantable devices containing nuclear receptor ligands for the treatment of vascular and related disorders
CA2718592A1 (en) 2008-02-13 2009-08-20 Keith Hruska Method of treating vascular sclerosis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0269408A3 (de) * 1986-11-26 1989-08-30 Genentech, Inc. TGF-Beta für die Behandlung von entzündlichen Erkrankungen
CA1338663C (en) * 1988-04-08 1996-10-22 Hermann Oppermann Biosynthetic osteogenic proteins and osteogenic devices containing them
WO1990000900A1 (en) * 1988-07-20 1990-02-08 Amgen Inc. Method of treating inflammatory disorders by reducing phagocyte activation
DE69032424T2 (de) * 1989-10-17 1999-02-04 Stryker Corp., Kalamazoo, Mich. Osteogene vorrichtungen
WO1992007073A1 (en) * 1990-10-18 1992-04-30 Creative Biomolecules, Inc. Osteogenic peptides
WO1992015323A1 (en) * 1991-03-11 1992-09-17 Creative Biomolecules, Inc. Protein-induced morphogenesis

Also Published As

Publication number Publication date
JPH06510989A (ja) 1994-12-08
JP3693338B2 (ja) 2005-09-07
CA2116562A1 (en) 1993-03-18
WO1993004692A1 (en) 1993-03-18
EP0601106B2 (de) 2003-11-05
AU669127B2 (en) 1996-05-30
CA2116562C (en) 1999-04-13
EP0601106A1 (de) 1994-06-15
ATE192931T1 (de) 2000-06-15
EP0601106B1 (de) 2000-05-17
DE69231062T2 (de) 2001-02-15
ES2149776T5 (es) 2004-07-01
DE69231062T3 (de) 2004-07-29
ES2149776T3 (es) 2000-11-16
AU2564592A (en) 1993-04-05

Similar Documents

Publication Publication Date Title
DE69231062D1 (de) Morphogen-induzierte Modulation von entzündlichen Antworten
ES2176232T3 (es) Vacuna adecuada para ser utilizada en la prevencion y tratamiento de la infeccion por helicobacter.
BR9106438A (pt) Composicoes terapeuticas sinergisticas e processos
FI944549A0 (fi) Allergisten ja tulehdussairauksien hoidossa käyttökelpoiset yhdisteet
LV10907A (lv) Interferona polietilenglikola atvasinajums
ES2120948T3 (es) Procedimiento y composiciones que mejoran los sintomas de la sepsis.
DE69434223D1 (de) In der behandlung von il4 auslösenden krankheiten nützliche rekombinante il4 antikörper
DK0744957T3 (da) Præparat og fremgangsmåde til forebyggelse og behandling af inflammation med immunoglobulin A
SE8404707D0 (sv) Komposition innehallande pyridinlosligt extrakt och raffinerat detoxifierat endotoxin samt anvendning derav
DK390585A (da) Kontrastmiddel og fremgangsmaade til anvendelse heraf
IT8319306A0 (it) Composizione di antralina oppure di uno dei suoi derivati in un estere aromatico e suo impiego nel trattamento di malattie della pelle e delle unghie.
IT8868118A0 (it) Composizione e procedimento per il trattamento e la cura dei capelli
ATE81004T1 (de) Laktamimide in der behandlung arzneiresistenter protozoeninjektionen.
IT8367917A0 (it) Forno combinato con un inceneritore di fumi per il trattamento di prodotti quali tessuti in pezza e procedimento per la sua utilizzazione
DK0579488T3 (da) Præparat til behandling af mastitis og matritis
ATE229981T1 (de) Glykolisierte cytokine
FI932759A0 (fi) Anvaendningen av IL-4 foer oekning av pao vacciners immunogener verkande immunreaktioner
NO921223L (no) Kombinasjonspreparat med antitrombotisk virkning
FI924215A (fi) Anvaendningen av il-4 foer oekning av immunreaktionen foerorsakad infektiosa antigen aemnen
DE69306559D1 (de) Neue kardioprotektive wirkstoffe
IT1203657B (it) Impiego in terapia di n-(dietilamminoetil)-2-metossi-5-metilsolfonil-benzammide e medicamento che la contiene
SE8900564D0 (sv) Novel medicinal use
ATE70440T1 (de) Verwendung von anipamil als artereosklerosemittel.
DK0552186T3 (da) Methol-derivat med spasmolytisk aktivitet
DE3777411D1 (de) Mittel zur verbesserung der perkutanen verabreichung von arzneimitteln.

Legal Events

Date Code Title Description
8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings
8327 Change in the person/name/address of the patent owner

Owner name: STRYKER CORP., KALAMAZOO, MICH., US

8328 Change in the person/name/address of the agent

Representative=s name: LICHTI PATENTANWAELTE, 76227 KARLSRUHE